Innoviva Statistics
Total Valuation
Innoviva has a market cap or net worth of $1.58 billion. The enterprise value is $1.30 billion.
| Market Cap | 1.58B |
| Enterprise Value | 1.30B |
Important Dates
The last earnings date was Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Innoviva has 73.81 million shares outstanding. The number of shares has increased by 44.23% in one year.
| Current Share Class | 73.81M |
| Shares Outstanding | 73.81M |
| Shares Change (YoY) | +44.23% |
| Shares Change (QoQ) | -0.49% |
| Owned by Insiders (%) | 0.91% |
| Owned by Institutions (%) | 101.15% |
| Float | 69.07M |
Valuation Ratios
The trailing PE ratio is 3.76 and the forward PE ratio is 10.71. Innoviva's PEG ratio is 0.31.
| PE Ratio | 3.76 |
| Forward PE | 10.71 |
| PS Ratio | 3.76 |
| Forward PS | 3.33 |
| PB Ratio | 1.18 |
| P/TBV Ratio | 1.38 |
| P/FCF Ratio | 8.69 |
| P/OCF Ratio | 8.61 |
| PEG Ratio | 0.31 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.75, with an EV/FCF ratio of 7.15.
| EV / Earnings | 2.58 |
| EV / Sales | 3.09 |
| EV / EBITDA | 6.75 |
| EV / EBIT | 7.82 |
| EV / FCF | 7.15 |
Financial Position
The company has a current ratio of 21.13, with a Debt / Equity ratio of 0.25.
| Current Ratio | 21.13 |
| Quick Ratio | 19.27 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 1.82 |
| Interest Coverage | 9.54 |
Financial Efficiency
Return on equity (ROE) is 50.72% and return on invested capital (ROIC) is 13.98%.
| Return on Equity (ROE) | 50.72% |
| Return on Assets (ROA) | 6.72% |
| Return on Invested Capital (ROIC) | 13.98% |
| Return on Capital Employed (ROCE) | 9.23% |
| Weighted Average Cost of Capital (WACC) | 5.99% |
| Revenue Per Employee | $2.65M |
| Profits Per Employee | $3.17M |
| Employee Count | 159 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 2.71 |
Taxes
In the past 12 months, Innoviva has paid $95.67 million in taxes.
| Income Tax | 95.67M |
| Effective Tax Rate | 15.94% |
Stock Price Statistics
The stock price has increased by +12.03% in the last 52 weeks. The beta is 0.38, so Innoviva's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +12.03% |
| 50-Day Moving Average | 22.92 |
| 200-Day Moving Average | 20.92 |
| Relative Strength Index (RSI) | 35.89 |
| Average Volume (20 Days) | 800,931 |
Short Selling Information
The latest short interest is 6.40 million, so 8.67% of the outstanding shares have been sold short.
| Short Interest | 6.40M |
| Short Previous Month | 6.28M |
| Short % of Shares Out | 8.67% |
| Short % of Float | 9.26% |
| Short Ratio (days to cover) | 10.45 |
Income Statement
In the last 12 months, Innoviva had revenue of $420.69 million and earned $504.34 million in profits. Earnings per share was $5.69.
| Revenue | 420.69M |
| Gross Profit | 311.74M |
| Operating Income | 166.22M |
| Pretax Income | 600.01M |
| Net Income | 504.34M |
| EBITDA | 192.70M |
| EBIT | 166.22M |
| Earnings Per Share (EPS) | $5.69 |
Balance Sheet
The company has $611.93 million in cash and $331.42 million in debt, with a net cash position of $280.51 million or $3.80 per share.
| Cash & Cash Equivalents | 611.93M |
| Total Debt | 331.42M |
| Net Cash | 280.51M |
| Net Cash Per Share | $3.80 |
| Equity (Book Value) | 1.34B |
| Book Value Per Share | 18.18 |
| Working Capital | 736.07M |
Cash Flow
In the last 12 months, operating cash flow was $183.60 million and capital expenditures -$1.62 million, giving a free cash flow of $181.97 million.
| Operating Cash Flow | 183.60M |
| Capital Expenditures | -1.62M |
| Depreciation & Amortization | 26.48M |
| Net Borrowing | -25,000 |
| Free Cash Flow | 181.97M |
| FCF Per Share | $2.47 |
Margins
Gross margin is 74.10%, with operating and profit margins of 39.51% and 119.88%.
| Gross Margin | 74.10% |
| Operating Margin | 39.51% |
| Pretax Margin | 142.63% |
| Profit Margin | 119.88% |
| EBITDA Margin | 45.81% |
| EBIT Margin | 39.51% |
| FCF Margin | 43.26% |
Dividends & Yields
Innoviva does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -44.22% |
| Shareholder Yield | -44.22% |
| Earnings Yield | 31.90% |
| FCF Yield | 11.51% |
Analyst Forecast
The average price target for Innoviva is $35.50, which is 65.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.50 |
| Price Target Difference | 65.73% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 2.71% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innoviva has an Altman Z-Score of 3 and a Piotroski F-Score of 5.
| Altman Z-Score | 3 |
| Piotroski F-Score | 5 |